Journal for immunotherapy of cancer, 2023
http://dx.doi.org/10.1136/jitc-2023-SITC2023.1132

#1132 STIMULATED TUMOR CELLS (STC) VACCINE INDUCE RESPONSE IN COLORECTAL CANCER

G. ALZEEB[1], C. GONGORA[2], C. RICHARD[3], R. BOIDOT[3], T. FORTIN[4], A. BESSEDE[5], Y. WANG[6], L. CHALUS[1], B. PINTEUR[1], P. BRAVETTI[1], C. TORTORELLI[1], A. ITALIANO[7]

During the SITC 38th Annual Meeting: San Diego, (USA) 1-5 Nov 23, Brenus published additional transcriptomic (RNA seq) and proteomic (LC/MS-MS[1]) data from different STC-1010 batches to complete vaccine characterization and confirm a robust **coverage of "difficult-to-treat" colorectal clinical mutations and phenotypes**.

Previously, bearing-CRC tumor mice were treated with a murine surrogate of STC-1010 and results showed an **Increased Median Overall Survival (mOS):** +40% in CRC CT26 Model.

STC-1010 response is evaluated via specific cytokine expression reflecting **pro-inflammatory** and **cytotoxic immune response** against CRC HT29 tumor in the in-Ovo CAM model[2] ; also confirmed by histological H&E staining and a reduction of metastasis.

Further, the Mixed-Lymphocytes-Assay (see below) reflects specific priming and activation of immune cells, with a **remarkable tumor killing by apoptosis of human colorectal cancer cell lines**; with a perfect reproducibility between different STC-1010 lots:



Fig 1. SW620 Tumor cell apoptosis revelation by caspase 3 mediated by DC-primed CD8+ at 72H (Purple = apoptotic cells)



Fig 2. Apoptosis index of HCT116 CRC Tumor cells by STC-1010 vs Ctrl at 72H (3 batches : STC-1010 RD1, STC-1010 RD2, STC-1010 RD3)



[1] Liquide Chromatography coupled to tandem Mass Spectrometry
[2] **Chorio-Allantoïc membrane (CAM) Model: a.** Upper Eggshell opening **b.** Treatment with STC-1010 at D2; D4. **c.** Peripheral blood mononuclear cell (PBMCs) where isolated. **d.** Different eggs bearing HT29-tumor cells were treated with collected *STC-1010-activated PMBCs* at D2, D4 and D7. **e.** Egg samples were collected (blood and tumor) to performed analysis *(INFg; IL-12; IL2 expression ; quantity of metastatic invasion and histological necrosis score were reported)*

	AUTHORS	RESULTS
SITC23	[1] George ALZEEB, Scientific Project Manager, Brenus Pharma, (Ph.D) [2] Céline CONGORA, Institut de Recherche en Cancérologie de Montpellier (Ph.D) [3] Corentin RICHARD, Centre Georges-François Leclerc, UMRCNRS6302, (PhD) [3] Romain BOIDOT, Centre Georges-François Leclerc, UMRCNRS6302, (M.D, Ph.D) [4] Tanguy FORTIN, CEO, Anaquant, (PhD) [5] Alban BESSEDE, CEO, Explicyte, (Ph.D) [6] Yan WANG, R&D Project Manager, Inovotion, (M.D, PhD) [1] Lionel CHALUS, LTO, Brenus Pharma [1] Benoit PINTEUR, CSO, Brenus Pharma, (Pharm D) [1] Paul BRAVETTI, CEO, Brenus Pharma, (Pharm D, MSc) [1] Corinne TORTORELLI, Medical Lead, Brenus Pharma, (Pharm. D., Ph.D) [7] Antoine ITALIANO, Early Phase Trials and Sarcoma Units, Institut Bergonie, (M.D, PhD)	SEE POSTER

ABOUT BRENUS

Brenus Pharma is a pioneering biotech startup reshaping the landscape of oncology with our innovative platform, generating cutting-edge cancer vaccines. Our STC Platform: "Stimulated-Tumor-Cells" is the first discovery platform that generates cancer vaccines, based on cells that are stimulated to reproduce antigenic relapsing-tumor signatures; and haptenized to educate the immune system against resistant tumors and prevent cancer recurrence.

For further information: www.brenus-pharma.com | contact@brenus-pharma.com